Dacarbazine 500mg Injection Franchise in Ahmedabad

Chemotherapy Injection Supplier in Bangalore

Dacarbazine Oncology Injection Distributor in Hyderabad

Cancer Treatment Injectable Franchise Opportunity in Jaipur

Oncology Injectable Stockist in Mumbai
Dacarbazine Injection Export & Manufacturing in Chandigarh

Home/Products /dacarbazine-500mg-injection

Dacarfen 500 Injection

Composition : Dacarbazine (500mg) Injection

Dosage Form : Injection

Packaging Type : Vial

Packaging : 500mg

Price : ₹1/-

Dacarfen 500 Injection contains Dacarbazine 500mg, a high-strength alkylating chemotherapy medication widely used in oncology for treating metastatic melanoma, Hodgkin’s lymphoma, and soft tissue sarcomas. With its potent cytotoxic action, it remains an essential part of several treatment regimens where dependable tumour suppression is required.

The 500mg strength is typically used in advanced cycles or higher-dosage chemotherapy protocols, providing strong clinical response and reliable therapeutic outcomes. Its well-established efficacy and long-standing usage in cancer therapy make it a standard choice across oncology departments.

For oncology distributors, institutional suppliers, and hospital procurement teams, Dacarfen 500 Injection is a high-frequency requirement due to its routine use in day-care chemotherapy centers, cancer speciality units, and multispecialty hospitals. Continuous treatment cycles ensure consistent market demand and regular purchase orders.

Integrating Dacarfen 500 into your oncology portfolio strengthens your chemotherapy and cancer-management segment, offering opportunities across private hospitals, government cancer programs, large-scale tenders, export markets, and third-party manufacturing projects. Its critical importance in cancer regimens makes it a high-value and strategically essential product for pharmaceutical distributors.

Read More

About the Product

Dacarfen 500 Injection contains Dacarbazine 500mg, a high-strength alkylating chemotherapy medication widely used in oncology for treating metastatic melanoma, Hodgkin’s lymphoma, and soft tissue sarcomas. With its potent cytotoxic action, it remains an essential part of several treatment regimens where dependable tumour suppression is required.

The 500mg strength is typically used in advanced cycles or higher-dosage chemotherapy protocols, providing strong clinical response and reliable therapeutic outcomes. Its well-established efficacy and long-standing usage in cancer therapy make it a standard choice across oncology departments.

For oncology distributors, institutional suppliers, and hospital procurement teams, Dacarfen 500 Injection is a high-frequency requirement due to its routine use in day-care chemotherapy centers, cancer speciality units, and multispecialty hospitals. Continuous treatment cycles ensure consistent market demand and regular purchase orders.

Integrating Dacarfen 500 into your oncology portfolio strengthens your chemotherapy and cancer-management segment, offering opportunities across private hospitals, government cancer programs, large-scale tenders, export markets, and third-party manufacturing projects. Its critical importance in cancer regimens makes it a high-value and strategically essential product for pharmaceutical distributors.

Common side effects may include nausea, vomiting, loss of appetite, fatigue, and temporary hair thinning. Some patients may experience low blood cell counts, liver function changes, or flu-like symptoms. Immediate medical attention is needed if severe allergic reactions or persistent vomiting occur.

Dacarfen 500 Injection is indicated for the treatment of metastatic malignant melanoma and Hodgkin’s lymphoma. It is used as part of combination chemotherapy regimens for better therapeutic outcomes.

This medicine must be administered strictly under the supervision of an experienced oncologist. Dose adjustments may be needed in patients with liver or kidney impairment. Avoid use during pregnancy or breastfeeding unless clearly prescribed. Regular blood tests are essential during therapy.

Store Dacarfen 500 Injection in a cool, dry place below 25°C. Keep the vial protected from light and out of the reach of children. Do not freeze. Use only the solution prepared by a healthcare professional.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation